Optic pathway gliomas in children with neurofibromatosis 1: Consensus statement from the NF1 optic pathway glioma task force

Annals of Neurology

Volumn 41, Issue 2, 1997, Pages 143-149

  Listernick, R ^a   Louis, D N ^a   Packer, R J ^a   Gutmann, D H ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; CARBOPLATIN; CORTICOSTEROID; PHENYLACETIC ACID; RETINOIC ACID; VINCRISTINE;

CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CHILD; CLINICAL FEATURE; FOLLOW UP; GENE THERAPY; HUMAN; MOLECULAR GENETICS; NEUROFIBROMATOSIS; NEUROPATHOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; OPTIC NERVE GLIOMA; PRECOCIOUS PUBERTY; PRIORITY JOURNAL; REVIEW; SCREENING;

EID: 0031044804     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.410410204     Document Type: Review

References (54)

1. 1 Riccardi VM. Neurofibromatosis: past, present and future. N Engl J Med 1991 ; 324: 1283–1285
2. 2 Knudson A. Antioncogenes and human cancer. Proc Natl Acad Sci USA 1993 ; 90: 10914–10921
3. 3 Cawthon RM, Weiss M, Xu G, et al. A major segment of the neurofibromatosis type 1 gene: cDNA sequence, genomic structure, and point mutations. Cell 1990 ; 62: 193–201
4. 4 Viskochil D, Buchberg AM, Xu G, et al. Deletions and a translocation interrupt a cloned gene at the neurofibromatosis type 1 locus. Cell 1990 ; 62: 187–192
5. 5 Wallace MR, Marchuk DA, et al. Type 1 neurofibromatosis gene: identification of a large transcript disrupted in three NF1 patients. Science 1990 ; 249: 181–186
6. 6 Xu G, O'Connell P, Viskochil D, et al. The neurofibromatosis type 1 gene encodes a protein related to GAP. Cell 1990 ; 62: 599–608
7. 7 Xu G, et al. The catalytic domain of the neurofibromatosis type 1 gene product stimulates ras GTPase and complements ira mutants of S cerevisiae. Cell 1990 ; 63: 835–841
8. 8 Martin GA, Viskochil D, Bollag G, et al. The GAP‐related domain of the neurofibromatosis type 1 gene product interacts with ras p21. Cell 1990 ; 63: 843–849
9. 9 Ballester R, Marchuk DA, Boguski M, et al. The NF1 locus encodes a protein functionally related to mammalian GAP and yeast IRA proteins. Cell 1990 ; 63: 851–859
10. 10 Basu TN, et al. Aberrant regulation of ras proteins in tumour cells from type 1 neurofibromatosis patients. Nature 1992 ; 356: 713–715
11. 11 DeClue JE, Papageorge AG, Fletcher JA, et al. Abnormal regulation of mammalian p21 ras contributes to malignant tumor growth in von Recklinghausen (type 1) neurofibromatosis. Cell 1992 ; 69: 265–273
12. 12 Gutmann DH. The neurofibromatoses: new insights into old problems. Curr Opin Neurol 1994 ; 7: 166–171
13. 13 Burger PC, Scheithauer BW, Vogel FS. Surgical pathology of the nervous system and its coverings. 3rd ed. New York: Churchill Livingstone, 1991
14. 14 Ilgren EB, Kinnier‐Wilson LM, Stiller CA. Gliomas in neurofibromatosis: a series of 89 cases with evidence for enhanced malignancy in associated cerebellar astrocytomas. Pathol Annu 1985 ; 20: 331–358
15. 15 Kleihues P, Burger PC, Scheithaur BW. Histological typing of tumours of the central nervous system. Berlin: Springer, 1993
16. 16 Russell DS, Rubinstein LJ. Pathology of tumours of the nervous system. Baltimore: Williams & Wilkins, 1989
17. 17 Borit A, Richardson EPJ. The biological and clinical behavior of pilocytic astrocytomas of the optic pathways. Brain 1982 ; 105: 161–187
18. 18 Rubinstein LJ. Pathological features of optic nerve and chiasmatic gliomas. Neurofibromatosis 1988 ; 1: 152–158
19. 19 Stern J, DiGiacinto GV, Housepian EM. Neurofibromatosis and optic glioma: clinical and morphological correlations. Neurosurgery 1979 ; 4: 524–528
20. 20 Stern J, Jacobiec FA, Housepian EM. The architecture of optic nerve gliomas with and without neurofibromatosis. Arch Ophthalmol 1980 ; 98: 505–548
21. 21 Burger PC, Scheithauer BE. Tumors of the central nervous system. Washington, DC: Armed Forces Institute of Pathology, 1994
22. 22 Louis DN, Edgerton S, Thor AD, Hedley‐Whyte ET. Proliferating cell nuclear antigen (PCNA) and Ki‐67 immunohistochemistry in brain tumors–a comparative study. Acta Neuropathol (Berl) 1991 ; 81: 675–679
23. 23 Louis DN, Meehan SM, Ferrante RJ, Hedley‐Whyte ET. Use of the silver nucleolar organizer region (AgNOR) technique in the differential diagnosis of central nervous system neoplasia. J Neuropathol Exp Neurol 1992 ; 51: 150–157
24. 24 Burnstine MA, Levin LA, Louis DN, et al. Nucleolar organizer regions in optic gliomas. Brain 1993 ; 116: 1465–1476
25. 25 von Deimling A, Louis DN, Menon AG, et al. Deletions on the long arm of chromosome 17 in pilocytic astrocytoma. Acta Neuropathol (Berl) 1993 ; 86: 81–85
26. 26 Louis DN, Seizinger BR, Cavenee WK. Molecular genetic basis of cerebral gliomas. Benign cerebral glioma. Lebanon, NH: American Association of Neurological Surgeons Publication, 1995
27. 27 Huson SM, Harper PS, Compston DAS. Von Recklinghausen neurofibromatosis: a clinical and population study in southeast Wales. Brain 1988 ; 111: 1355–1381
28. 28 Lewis RA, et al. Von Recklinghausen neurofibromatosis. II. Incidence of optic gliomata. Ophthalmology 1984 ; 91: 929–935
29. 29 Listernick R, Charrow J, Greenwald MJ, Esterly NB. Optic gliomas in children with neurofibromatosis type 1. J Pediatr 1989 ; 114: 788–792
30. 30 Listernick R, Charrow, J, Greenwald MJ, Mets M. Natural history of optic pathway tumors in children with neurofibromatosis type 1: a longitudinal study. J Pediatr 1994 ; 125: 63–66
31. 31 Habiby R, Silverman B, Listernick R, Charrow J. Precocious puberty in children with neurofibromatosis type 1. J Pediatr 1995 ; 126: 364–367
32. 32 Alvord EC, Lofton S. Gliomas of the optic nerve or chiasm. J Neurosurg 1988 ; 68: 85–98
33. 33 Listernick R, Darling C, et al. Optic pathway tumors in children: the effect of neurofibromatosis type 1 on clinical manifestations and natural history. J Pediatr 1995 ; 127: 718–722
34. 34 Haik BG, Saint Louis L, Bierly J, et al. Magnetic resonance imaging in the evaluation of optic nerve gliomas. Ophthalmology 1987 ; 94: 709–717
35. 35 Castillo M, Green C, Kwock L, et al. Proton MR spectroscopy in patients with neurofibromatosis type 1: evaluation of hamartomas and clinical correlation. AJNR 1995 ; 16: 141–147
36. 36 North K, Cochineas C, Tang E, Fagan E. Optic gliomas in neurofibromatosis type 1: role of visual evoked potentials. Pediatr Neurol 1994 ; 10: 117–123
37. 37 Rossi LN, Pastorino G, Scotti G, et al. Early diagnosis of optic glioma in children with neurofibromatosis type 1. Childs Nerv Syst 1994 ; 10: 426–429
38. 38 Glaser JS, Hoyt WF, Corbett J. Visual morbidity with chiasmal glioma. Arch Ophthalmol 1971 ; 85: 3–12
39. 39 Fletcher WA, Imes RK, Hoyt WF. Chiasmatic gliomas: appearance and long‐term changes demonstrated by computed tomography. J Neurosurg 1986 ; 65: 154–159
40. 40 Packer RJ, Bilaniuk LT, Cohen BH, et al. Intracranial visual pathway gliomas in children with neurofibromatosis. Neurofibromatosis 1988 ; 1: 212–222
41. 41 Packer RJ, Savino PJ, et al. Chiasmatic gliomas of childhood: a reappraisal of natural history and effectiveness of cranial irradiation. Childs Brain 1983 ; 10: 393–402
42. 42 Janss AJ, Grundy R, Craan A. Optic pathway and hypothalamic/chiasmic gliomas in children under age 5 with six‐year follow‐up. Cancer 1995 ; 75: 1051–1059
43. 43 Danoff BF, Kramer S, Thompson N. The radiotherapeutic management of optic gliomas of children. Int J Radiat Oncol Biol Phys 1980 ; 6: 45–50
44. 44 Flickinger SC, Torres C, Deutsch M. Management of low grade gliomas of the optic nerve and chiasm. Cancer 1988 ; 61: 635–642
45. 45 Jenkin D, Angyalfi S, Becker L, et al. Optic glioma in children: surveillance, resection or irradiation. Int J Radiat Oncol Biol Phys 1993 ; 25: 215–225
46. 46 Baram TX, Moser RP, Van Eyes J. Surgical management of progressive visual loss in optic gliomas of childhood. Ann Neurol 1986 ; 20: 398
47. 47 Sutton LN, Molloy P, Srnyak H, et al. Long‐term outcome of hypothalamic/chiasmatic astrocytomas in children with conservative surgery. J Neurosurg 1995 ; 83: 583–589
48. 48 Packer RJ, Sutton LM, et al. Treatment of chiasmatic/hypothalamic gliomas of childhood with chemotherapy: an update. Ann Neurol 1988 ; 23: 79–85
49. 49 Chamberlain MC, Arafe MR. Recurrent chiasmatic‐hypothalamic glioma treated with oral etoposide. J Clin Oncol 1995 ; 13: 2072–2076
50. 50 Friedman HS, Krischer JP, Burger P, et al. Treatment of children with progressive or recurrent brain tumors with carboplatin or iproplatin: a Pediatric Oncology Group randomized phase II study. J Clin Oncol 1992 ; 10: 249–256
51. 51 Gajjar A, Heideman RL, Kovnar EH, et al. Response of pediatric low‐grade gliomas to chemotherapy. Pediatr Neurosurg 1992 ; 19: 113–121
52. 52 Pons MA, Finlay JL, Walker RW, et al. Chemotherapy with vincristine and etoposide in children with low‐grade astrocytoma. J Neurooncol 1992 ; 14: 151–158
53. 53 Rosenstock JG, Packer RJ, et al. Chiasmatic optic glioma treated with chemotherapy. A preliminary report. J Neurosurg 1985 ; 63: 862–866
54. 54 Packer RJ, Lange B, Ater J, et al. Carboplatin and vincristine for progressive low‐grade gliomas of childhood. J Clin Oncol 1992 ; 11: 850–857